Bruce E Sands is an expert in Gastroenterology at Icahn School of Medicine at Mount Sinai (United States). As of October 2026, ScienceLeadR ranks Bruce E Sands in the top 1% of experts worldwide for Crohn Disease, Inflammatory Bowel Diseases and Gastroenteritis. Bruce E Sands has authored 1,121 publications, the most recent in 2026, and is an investigator in 50 clinical trials, 5 of them ongoing. SLR score: 5,523 (community average: 125). How the SLR is computed.

LeadR Profile

Bruce E Sands Icahn School of Medicine at Mount Sinai United States
5 523 ScienceLeadR Reputation 5523
Network Map

Gastroenterology

Subspecialties: Hepatology - Public Health - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1995 - 2026

Source: PubMed

Icahn School of Medicine at Mount Sinai

Publications Synthesis

Sources: PubMed, OpenAlex

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Endoscopic and histologic healing distribution and persistent rectosigmoiditis in moderate-to-severe ulcerative colitis.
PMID 42905967 — colon, descending, colitis, crohn disease, colon, rectum, inflammatory bowel diseases, colitis, ulcerative
Inflamm Bowel Dis20260
Maintenance of Efficacy Outcomes at Week 52 among Etrasimod Induction Responders: An Analysis from the Phase 3 ELEVATE UC 52 Trial.
PMID 42848715 — maintenance
Dig Dis20260
IOIBD: the International Organization for the Study of Inflammatory Bowel Disease.
PMID 42553409 — inflammatory bowel diseases, research, education
Ther Adv Gastroenterol20260
Subcutaneous infliximab in the treatment of patients with perianal fistulizing Crohn's disease: current evidence and emerging roles.
PMID 42488031 — fistula, safety, crohn disease, therapeutics, infliximab
Ther Adv Gastroenterol20260
Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial.
PMID 42462750 — liver diseases, colitis, safety, probability, drug-related side effects and adverse reactions, therapeutics, gastrointestinal diseases, colitis, ulcerative
Lancet Gastroenterol Hepatol Top journal20267

Clinical Studies 50

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 2 19
Phase 3 18
N/A 4
Phase 4 4
Phase 1 3
Phase 2/Phase 3 2

By status:

Completed 36
Active not recruiting 5
Terminated 5
Recruiting 4

By type:

Interventional 49
Observational 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 3
multicentric5to9 1
multicentricup10 43

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
VECTORS A Study to Evaluate Transmural Healing as a Treatment Target in Crohn s Disease
NCT06257706 — crohn disease, adrenal cortex hormones, biomarkers, signs and symptoms, therapeutics
Phase 4Recruiting2024
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn s Disease
NCT06227910 — safety, crohn disease, pharmaceutical preparations, tablets, drug therapy, maintenance, capsules, therapeutics
Phase 3Recruiting2025
A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis
NCT06080048 — colitis, safety, ulcer, healthy volunteers, capsules, colitis, ulcerative, pharmacokinetics
Phase 1Recruiting2023
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn s Disease
NCT05197049 — injections, safety, crohn disease, therapeutics
Phase 3Active not recruiting2022
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease The OPTIMIZE Trial
NCT04835506 — colitis, crohn disease, inflammatory bowel diseases, colitis, ulcerative, infliximab
Phase 4Active not recruiting2021

LeadR Networks

Main global connection map